

| Sample | Anonymous ID | Group           | OCI    | OCI   | No. ATL-like clones detected | Freq. of most expanded clone (% of CD8+ cells) | PVL at time of sample | Lymphocyte count    | Diagnosis                     | Immunotherapy or chemo in past 6/52                | Sex   | Age at time of sample | Strongyloides | Ethnicity                    | FHs ATL           | Outcome | Years follow up | Adjusted years follow up |
|--------|--------------|-----------------|--------|-------|------------------------------|------------------------------------------------|-----------------------|---------------------|-------------------------------|----------------------------------------------------|-------|-----------------------|---------------|------------------------------|-------------------|---------|-----------------|--------------------------|
| 238    | ATL_1        | Training-ATL    | <0.770 | 0.620 | 0                            | n/a                                            | 2.1                   | 0.7                 | ATL Lymphoma, HIV Co-infected | Post CHOP x 6, REPC                                | m     | 68.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 60     | ATL_2        | Training-ATL    | >0.770 | 0.828 | 1                            | 68.8                                           | 51.4                  | Missing data        | Acute ATL                     | Prednisolone                                       | f     | 74.0                  | Positive      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 47     | ATL_3        | Training-ATL    | >0.770 | 0.369 | 1                            | n/a                                            | 83.2                  | 21.7                | Chronic ATL                   | Zidovudine/interferon alpha                        | f     | 64.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 24     | ATL_4        | Training-ATL    | >0.770 | 0.999 | 1                            | n/a                                            | n/a                   | 37.6                | 22.8                          | Acute ATL                                          | No Rx | f                     | 76.0          | Unknown                      | Black             | n/a     | n/a             | n/a                      |
| 65     | ATL_5        | Training-ATL    | <0.770 | 0.638 | 0                            | n/a                                            | n/a                   | 1.7                 | Missing data                  | Cutaneous ATL                                      | No Rx | f                     | 56.0          | Negative                     | Black             | n/a     | n/a             | n/a                      |
| 241    | ATL_6        | Training-ATL    | >0.770 | 0.775 | 1                            | 5.6                                            | 17.7                  | 1.6                 | ATL Lymphoma                  | #2 chemo (gem/Cis x 1, Gem/Carb x 1, DTX, ZDV/IFN) | f     | 61.0                  | Unknown       | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 61     | ATL_7        | Training-ATL    | >0.770 | 0.940 | 1                            | 40.9                                           | 17.9                  | 3.2                 | Chronic ATL                   | No Rx                                              | f     | 58.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 57     | ATL_8        | Training-ATL    | >0.770 | 0.996 | 1                            | 99.8                                           | 42.1                  | 12.2                | Chronic ATL                   | No Rx                                              | m     | 51.0                  | Positive      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 242    | ATL_9        | Training-ATL    | <0.770 | 0.122 | 0                            | n/a                                            | 7.9                   | 1.0                 | ATL Lymphoma                  | #6 Gem/Cis                                         | f     | 63.0                  | Unknown       | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 74     | ATL_10       | Training-ATL    | >0.770 | 0.821 | 1                            | 10.7                                           | 22.1                  | 1.5                 | Chronic ATL                   | Multiple lines chemotherapy/Mogamulizumab          | f     | 57.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 58     | ATL_11       | Training-ATL    | >0.770 | 0.973 | 2                            | 71.1                                           | 181.0                 | 42.2                | Acute ATL                     | Zidovudine/interferon alpha                        | f     | 71.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 233    | ATL_12       | Training-ATL    | <0.770 | 0.684 | 0                            | n/a                                            | 2.2                   | 0.5                 | ATL Lymphoma                  | Post #4 CHOP                                       | m     | 67.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 59     | ATL_13       | Training-ATL    | >0.770 | 0.996 | 1                            | 84.3                                           | 17.7                  | 0.1                 | Acute ATL                     | 3 x CHOP, Zidovudine                               | f     | 61.0                  | Unknown       | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 51     | ATL_14       | Training-ATL    | >0.770 | 0.900 | 1                            | 62.4                                           | 54.5                  | 3.1                 | Acute ATL                     | Mogamulizumab                                      | m     | 61.0                  | Positive      | Black possible               | n/a               | n/a     | n/a             | n/a                      |
| 234    | ATL_15       | Training-ATL    | <0.770 | 0.727 | 0                            | n/a                                            | 10.9                  | 1.3                 | ATL Lymphoma                  | 3 x CHOP, Zidovudine then stopped 6/9/16           | f     | 59.0                  | Unknown       | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 55     | ATL_16       | Training-ATL    | <0.770 | 0.760 | 0                            | n/a                                            | 3.5                   | 2.5**               | ATL Lymphoma                  | No Rx                                              | m     | 53.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 52     | ATL_17       | Training-ATL    | >0.770 | 0.772 | 0                            | n/a                                            | n/a                   | 1.2                 | ATL Lymphoma                  | No Rx                                              | f     | 54.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 53     | ATL_18       | Training-ATL    | >0.770 | 0.999 | 1                            | 96.7                                           | 56.1                  | 6.3                 | Acute ATL                     | No Rx                                              | m     | 39.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 54     | ATL_19       | Training-ATL    | <0.770 | 0.745 | 0                            | n/a                                            | 1.9                   | 2.1                 | Cutaneous ATL                 | No Rx                                              | f     | 85.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 69     | ATL_20       | Training-ATL    | >0.770 | 0.995 | 1                            | 84.9                                           | 56.0                  | 10.8                | Chronic ATL                   | No Rx                                              | m     | 59.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 235    | ATL_21       | Training-ATL    | <0.770 | 0.694 | 0                            | n/a                                            | 6.7                   | 2.7**               | ATL Lymphoma                  | Post #6 CHOP                                       | f     | 49.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 48     | ATL_22       | Training-ATL    | >0.770 | 0.984 | 1                            | 75.4                                           | 23.4                  | 3.1                 | ATL Lymphoma                  | No Rx                                              | f     | 68.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 49     | ATL_23       | Training-ATL    | >0.770 | 0.993 | 1                            | 79.8                                           | 86.5                  | 6.0                 | Chronic ATL                   | No Rx                                              | f     | 37.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 64     | ATL_24       | Training-ATL    | >0.770 | 0.999 | 1                            | 94.4                                           | 99.5                  | 9.7                 | Acute ATL                     | Zidovudine/interferon alpha                        | m     | 51.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 236    | ATL_25       | Training-ATL    | >0.770 | 0.980 | 1                            | 81.7                                           | 39.7                  | 3.0                 | ATL Lymphoma                  | CHOP x 4, ICE- refractory                          | f     | 35.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 237    | ATL_26       | Training-ATL    | <0.770 | 0.674 | 0                            | n/a                                            | 4.4                   | 1.2                 | ATL Lymphoma                  | Post #2 CHOP                                       | f     | 65.0                  | Positive      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 50     | ATL_27       | Training-ATL    | >0.770 | 0.979 | 1                            | 81.9                                           | 46.3                  | Missing data        | Acute ATL                     | No Rx                                              | f     | 66.0                  | Negative      | Middle Eastern               | n/a               | n/a     | n/a             | n/a                      |
| 67     | ATL_28       | Training-ATL    | >0.770 | 0.826 | 1                            | 10.2                                           | 3.4                   | 0.3                 | Acute ATL                     | Cycle 5 day 14 CHOP                                | f     | 46.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 215    | ATL_29       | Training-ATL    | >0.770 | 0.989 | 1                            | 88.1                                           | 45.4                  | 9.6                 | Chronic ATL                   | No Rx                                              | f     | 35.0                  | Negative      | Other                        | n/a               | n/a     | n/a             | n/a                      |
| 230    | ATL_30       | Training-ATL    | >0.770 | 0.993 | 1                            | 76.1                                           | 15.3                  | Missing data        | Chronic ATL                   | Zidovudine only                                    | m     | 69.0                  | Unknown       | Middle Eastern               | n/a               | n/a     | n/a             | n/a                      |
| 39     | No ATL_1     | Training-No ATL | <0.770 | 0.724 | 0                            | n/a                                            | 1.2                   | 1.4                 | AC                            | No Rx                                              | f     | 73.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 32     | No ATL_2     | Training-No ATL | <0.770 | 0.697 | 0                            | n/a                                            | 9.0                   | 1.8                 | AC                            | No Rx                                              | f     | 67.0                  | Unknown       | Middle Eastern               | n/a               | n/a     | n/a             | n/a                      |
| 240    | No ATL_3     | Training-No ATL | <0.770 | 0.720 | 0                            | n/a                                            | 15.2                  | 2.2                 | AC                            | No Rx                                              | f     | 32.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 25     | No ATL_4     | Training-No ATL | <0.770 | 0.664 | 0                            | n/a                                            | 0.9                   | 2.0                 | AC                            | No Rx                                              | f     | 62.0                  | Positive      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 239    | No ATL_5     | Training-No ATL | <0.770 | 0.645 | 0                            | n/a                                            | 3.9                   | 2.6                 | AC                            | No Rx                                              | m     | 49.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 41     | No ATL_6     | Training-No ATL | <0.770 | 0.707 | 0                            | n/a                                            | 4.7                   | 1.6                 | AC                            | No Rx                                              | f     | 54.0                  | Unknown       | Black possible               | n/a               | n/a     | n/a             | n/a                      |
| 246    | No ATL_7     | Training-No ATL | <0.770 | 0.682 | 0                            | n/a                                            | 6.7                   | 1.0                 | AC                            | n/a                                                | n/a   | 54.0                  | Unknown       | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 5      | No ATL_8     | Training-No ATL | <0.770 | 0.641 | 0                            | n/a                                            | 1.9                   | 1.9                 | AC                            | No Rx                                              | f     | 50.0                  | Positive      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 3      | No ATL_9     | Training-No ATL | <0.770 | 0.616 | 0                            | n/a                                            | 0.1                   | Missing data        | No Rx                         | f                                                  | 39.0  | Negative              | Black         | n/a                          | n/a               | n/a     | n/a             |                          |
| 6      | No ATL_10    | Training-No ATL | <0.770 | 0.577 | 0                            | n/a                                            | 3.0                   | 1.5                 | AC                            | No Rx                                              | f     | 38.0                  | Negative      | Indian/Pakistani/Bangladeshi | n/a               | n/a     | n/a             | n/a                      |
| 40     | No ATL_11    | Training-No ATL | <0.770 | 0.605 | 0                            | n/a                                            | 1.9                   | 1.6                 | AC                            | No Rx                                              | f     | 62.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 13     | No ATL_12    | Training-No ATL | <0.770 | 0.611 | 0                            | n/a                                            | 7.9                   | 3.4                 | AC                            | No Rx                                              | f     | 57.0                  | Negative      | White                        | n/a               | n/a     | n/a             | n/a                      |
| 7      | No ATL_13    | Training-No ATL | <0.770 | 0.728 | 0                            | n/a                                            | 27.9                  | 1.6                 | AC                            | No Rx                                              | f     | 67.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 28     | No ATL_14    | Training-No ATL | <0.770 | 0.716 | 0                            | n/a                                            | 7.2                   | Missing data        | AC                            | No Rx                                              | m     | 21.0                  | Negative      | White                        | n/a               | n/a     | n/a             | n/a                      |
| 8      | No ATL_15    | Training-No ATL | <0.770 | 0.669 | 0                            | n/a                                            | 4.9                   | 1.1                 | AC                            | No Rx                                              | m     | 50.0                  | Positive      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 164    | No ATL_16    | Training-No ATL | <0.770 | 0.658 | 0                            | n/a                                            | 2.5                   | 2.3                 | AC                            | No Rx                                              | f     | 62.0                  | Negative      | White                        | n/a               | n/a     | n/a             | n/a                      |
| 166    | No ATL_17    | Training-No ATL | <0.770 | 0.637 | 0                            | n/a                                            | 1.9                   | 1.4                 | AC                            | No Rx                                              | f     | 41.0                  | Unknown       | White                        | n/a               | n/a     | n/a             | n/a                      |
| 250    | No ATL_18    | Training-No ATL | <0.770 | 0.728 | 0                            | n/a                                            | 15.4                  | Missing data        | N                             | No Rx                                              | f     | 55.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 251    | No ATL_19    | Training-No ATL | <0.770 | 0.715 | 0                            | n/a                                            | 12.4                  | 2.2                 | P                             | No Rx                                              | f     | 62.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 232    | No ATL_20    | Training-No ATL | <0.770 | 0.714 | 0                            | n/a                                            | 12.9                  | Missing data        | S                             | No Rx                                              | f     | 59.0                  | Positive      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 9      | No ATL_21    | Training-No ATL | <0.770 | 0.599 | 0                            | n/a                                            | 11.4                  | 1.8                 | HAM                           | No Rx                                              | f     | 63.0                  | Positive      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 243    | No ATL_22    | Training-No ATL | <0.770 | 0.716 | 0                            | n/a                                            | 13.0                  | Missing data        | HAM                           | No Rx                                              | f     | 69.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 34     | No ATL_23    | Training-No ATL | <0.770 | 0.710 | 0                            | n/a                                            | 5.8                   | Missing data        | HAM                           | No Rx                                              | m     | 78.0                  | Unknown       | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 10     | No ATL_24    | Training-No ATL | <0.770 | 0.637 | 0                            | n/a                                            | 11.4                  | 2.2                 | HAM                           | Methotrexate                                       | f     | 60.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 244    | No ATL_25    | Training-No ATL | <0.770 | 0.708 | 0                            | n/a                                            | 8.1                   | 2.7                 | HAM                           | No Rx                                              | f     | 74.0                  | Positive      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 245    | No ATL_26    | Training-No ATL | <0.770 | 0.648 | 0                            | n/a                                            | 68.6                  | 2.0                 | HAM                           | No Rx                                              | f     | 65.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 27     | No ATL_27    | Training-No ATL | <0.770 | 0.721 | 0                            | n/a                                            | 27.4                  | 1.4                 | HAM                           | No Rx                                              | m     | 71.0                  | Unknown       | White                        | n/a               | n/a     | n/a             | n/a                      |
| 188    | No ATL_28    | Training-No ATL | <0.770 | 0.699 | 0                            | n/a                                            | 25.3                  | 4.4***              | HAM                           | Cyclosporin                                        | f     | 52.0                  | Negative      | White                        | n/a               | n/a     | n/a             | n/a                      |
| 14     | No ATL_29    | Training-No ATL | <0.770 | 0.720 | 0                            | n/a                                            | 34.7                  | 5.2***              | HAM                           | No Rx                                              | f     | 21.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 15     | No ATL_30    | Training-No ATL | <0.770 | 0.628 | 0                            | n/a                                            | 6.7                   | 1.6                 | HAM                           | No Rx                                              | f     | 52.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 33     | No ATL_31    | Training-No ATL | <0.770 | 0.714 | 0                            | n/a                                            | 9.4                   | 2.0                 | HAM                           | Cyclosporin                                        | f     | 50.0                  | Positive      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 16     | No ATL_32    | Training-No ATL | <0.770 | 0.690 | 0                            | n/a                                            | 7.8                   | 1.6                 | HAM                           | No Rx                                              | f     | 60.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 11     | No ATL_33    | Training-No ATL | <0.770 | 0.651 | 0                            | n/a                                            | 5.3                   | 1.2                 | HAM                           | No Rx                                              | f     | 52.0                  | Positive      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 17     | No ATL_34    | Training-No ATL | <0.770 | 0.684 | 0                            | n/a                                            | 14.0                  | Missing data        | HAM                           | No Rx                                              | m     | 66.0                  | Positive      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 18     | No ATL_35    | Training-No ATL | <0.770 | 0.623 | 0                            | n/a                                            | 4.0                   | 2.7                 | HAM                           | No Rx                                              | m     | 50.0                  | Positive      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 12     | No ATL_36    | Training-No ATL | <0.770 | 0.692 | 0                            | n/a                                            | 36.5                  | 3.3                 | HAM                           | No Rx                                              | f     | 62.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 29     | No ATL_37    | Training-No ATL | <0.770 | 0.726 | 0                            | n/a                                            | 3.7                   | 1.5                 | HAM                           | No Rx                                              | m     | 64.0                  | Negative      | White                        | n/a               | n/a     | n/a             | n/a                      |
| 253    | No ATL_38    | Training-No ATL | <0.770 | 0.678 | 0                            | n/a                                            | 6.1                   | Missing data        | HAM                           | No Rx                                              | f     | 35.0                  | Negative      | Black                        | n/a               | n/a     | n/a             | n/a                      |
| 269    | Screening_1  | Screening       | <0.770 | 0.647 | 0                            | n/a                                            | 0.9                   | 2.0                 | AC, HIV Co-infected           | No Rx                                              | f     | 55.0                  | Negative      | Black                        | Did not transform | 1.17    | 1.17            |                          |
| 170    | Screening_2  | Screening       | <0.770 | 0.660 | 0                            | n/a                                            | 0.2                   | 1.6                 | AC, HIV Co-infected           | No Rx                                              | f     | 65.0                  | Unknown       | Black                        | Did not transform | 1.05    | 1.05            |                          |
| 201    | Screening_3  | Screening       | <0.770 | 0.656 | 0                            | n/a                                            | 22.0                  | 2.6                 | AC, HIV Co-infected           | No Rx                                              | m     | 58.0                  | Unknown       | Black                        | Did not transform | 1.71    | 1.71            |                          |
| 271    | Screening_4  | Screening       | <0.770 | 0.614 | 0                            | n/a                                            | 1.2                   | Missing data        | AC, HIV Co-infected           | No Rx                                              | m     | 60.0                  | Negative      | Black                        | Did not transform | 0.62    | 0.62            |                          |
| 22     | Screening_5  | Screening       | >0.770 | 0.985 | 2                            | 14.3                                           | Missing data          | AC, HIV Co-infected | No Rx                         | f                                                  | 59.0  | Unknown               | Black         | Lost to follow-up            | 0.00              | 0.00    |                 |                          |
| 209    | Screening_6  | Screening       | >0.770 | 0.797 | 1                            | 5.2                                            | 13.7                  | 2.5                 | AC, HIV Co-infected           | No Rx                                              | f     | 46.0                  | Unknown       | Black                        | Did not transform | 2.26    | 2.26            |                          |
| 217    | Screening_7  | Screening       | <0.770 | 0.625 | 0                            | n/a                                            | 4.2                   | Missing data        | AC, HIV Co-infected           | No Rx                                              | m     | 73.0                  | Negative      | White                        | Did not transform | 1.27    | 1.27            |                          |
| 203    | Screening_8  | Screening       | <0.770 | 0.716 | 0                            | n/a                                            | 16.7                  | 2.7                 | HAM, HIV Co-infected          | Hydroxychloroquine                                 | f     | 43.0                  | Unknown       | Black                        | Did not transform | 1.36    | 1.36            |                          |
| 194    | Screening_9  | Screening       | <0.770 | 0.686 | 0                            | n/a                                            | 14.5                  | 3.0                 | AC, HIV Co-infected           | No Rx                                              | m     | 53.0                  | Unknown       | Black                        | Lost to follow-up | 0.00    | 0.00            |                          |
| 204    | Screening_10 | Screening       | <0.770 | 0.670 | 0                            | n/a                                            | 16.7                  | 2.9                 | AC, HIV Co-infected           | No Rx                                              | f     | 40.0                  | Unknown       | Black                        | Did not transform | 1.07    | 1.07            |                          |
| 99     | Screening_11 | Screening       | <0.770 | 0.707 | 0                            | n/a                                            | 23.3                  | 1.8                 | Anthraxis                     | Etanercept                                         | m     | 47.0                  | Unknown       | White                        | Did not transform | 1.69    | 1.69            |                          |
| 89     | Screening_12 | Screening       | <0.770 | 0.688 | 0                            | n/a                                            | 4.1                   | 1.9                 | Anthraxis                     | Methotrexate                                       | f     | 55.0                  | Negative      | Black                        | Did not transform | 1.59    | 1.59            |                          |
| 38     | Screening_13 | Screening       | <0.770 | 0.728 | 0                            | n/a                                            | 5.6                   | 1.6                 | AC                            | No Rx                                              | f     | 75.0                  | Negative      | Black                        | Lost to follow-up | 4.00    | 4.00            |                          |
| 116    | Screening_14 | Screening       | <0.770 | 0.606 | 0                            | n/a                                            | 1.5                   | Missing data        | AC                            | No Rx                                              | f     | 25.0                  | Unknown       | Black                        | Did not transform | 1.07    | 1.07            |                          |
| 178    | Screening_15 | Screening       | <0.770 | 0.586 | 0                            | n/a                                            | 1.2                   | Missing data        | AC                            | No Rx                                              | f     | 35.0                  | Unknown       | Black                        | Lost to follow-up | 1.61    | 1.61            |                          |
| 4      |              |                 |        |       |                              |                                                |                       |                     |                               |                                                    |       |                       |               |                              |                   |         |                 |                          |

|     |               |           |        |       |   |      |      |              |               |                                                       |   |      |          |                            |                   |      |         |
|-----|---------------|-----------|--------|-------|---|------|------|--------------|---------------|-------------------------------------------------------|---|------|----------|----------------------------|-------------------|------|---------|
| 186 | Screening_48  | Screening | <0.770 | 0.739 | 0 | n/a  | 4.9  | 2.5          | AC            | No Rx                                                 | f | 39.0 | Negative | Black                      | Did not transform | 1.10 | 1.10    |
| 195 | Screening_49  | Screening | <0.770 | 0.684 | 0 | n/a  | 12.9 | 1.8          | AC            | No Rx                                                 | f | 39.0 | Unknown  | Black                      | Lost to followup  | 0.00 | 0.50    |
| 257 | Screening_50  | Screening | <0.770 | 0.634 | 0 | n/a  | 2.8  | Missing data | AC            | No Rx                                                 | m | 80.0 | Unknown  | Black                      | Did not transform | 0.52 | 0.52    |
| 135 | Screening_51  | Screening | <0.770 | 0.652 | 0 | n/a  | 2.3  | 2.5          | AC            | No Rx                                                 | f | 52.0 | Negative | Middle Eastern             | Did not transform | 1.00 | 1.00    |
| 273 | Screening_52  | Screening | <0.770 | 0.622 | 0 | n/a  | 0.3  | 2.0          | AC            | No Rx                                                 | f | 83.0 | Negative | Black                      | Did not transform | 1.57 | 1.57    |
| 92  | Screening_53  | Screening | <0.770 | 0.754 | 0 | n/a  | 9.5  | 1.2          | AC            | No Rx                                                 | f | 66.0 | Negative | Black                      | Did not transform | 1.63 | 1.63    |
| 274 | Screening_54  | Screening | <0.770 | 0.613 | 0 | n/a  | 0.6  | 1.1          | AC            | No Rx                                                 | f | 57.0 | Unknown  | Other                      | Did not transform | 1.41 | 1.41    |
| 187 | Screening_55  | Screening | <0.770 | 0.730 | 0 | n/a  | 5.2  | 2.4          | AC            | No Rx                                                 | f | 53.0 | Negative | Black                      | Did not transform | 2.27 | 2.27    |
| 196 | Screening_56  | Screening | >0.770 | 0.834 | 1 | 18.0 | 18.4 | Missing data | AC            | No Rx                                                 | f | 57.0 | Unknown  | Black                      | Did not transform | 1.38 | 1.38    |
| 275 | Screening_57  | Screening | <0.770 | 0.598 | 0 | n/a  | 0.6  | Missing data | AC            | No Rx                                                 | f | 28.0 | Unknown  | Middle Eastern             | Did not transform | 0.55 | 0.55    |
| 56  | Screening_58  | Screening | >0.770 | 0.846 | 1 | 28.3 | 25.8 | 4.8****      | AC            | No Rx                                                 | f | 48.0 | Unknown  | Black                      | Transformed       | 5.82 | 5.82    |
| 260 | Screening_59  | Screening | >0.770 | 0.905 | 1 | 62.8 | 20.5 | 4.4****      | AC            | No Rx                                                 | f | 76.0 | Unknown  | Black                      | Transformed       | 3.45 | 3.45    |
| 70  | Screening_60  | Screening | >0.770 | 0.880 | 2 | 18.1 | 15.5 | Missing data | AC            | No Rx                                                 | m | 51.0 | Negative | Black                      | Treated           | 2.93 | exclude |
| 159 | Screening_61  | Screening | <0.770 | 0.586 | 0 | n/a  | 4.0  | 1.4          | Neurological  | No Rx                                                 | f | 53.0 | Unknown  | Black                      | Did not transform | 2.77 | 2.77    |
| 152 | Screening_62  | Screening | <0.770 | 0.768 | 0 | n/a  | 1.4  | 2.2          | Neurological  | No Rx                                                 | m | 51.0 | Negative | Black                      | Lost to followup  | 0.00 | 0.50    |
| 153 | Screening_63  | Screening | <0.770 | 0.769 | 0 | n/a  | 9.1  | Missing data | Neurological  | No Rx                                                 | m | 76.0 | Unknown  | Black                      | Lost to followup  | 0.17 | 0.67    |
| 154 | Screening_64  | Screening | <0.770 | 0.668 | 0 | n/a  | 5.0  | 1.6          | Neurological  | No Rx                                                 | f | 43.0 | Negative | Black                      | Lost to followup  | 0.00 | 0.50    |
| 120 | Screening_65  | Screening | <0.770 | 0.689 | 0 | n/a  | 11.6 | 1.5          | Neurological  | No Rx                                                 | f | 63.0 | Negative | Black                      | Did not transform | 1.33 | 1.33    |
| 93  | Screening_66  | Screening | >0.770 | 0.795 | 1 | 3.0  | 8.3  | 2.6          | Neurological  | No Rx                                                 | f | 63.0 | Unknown  | Black                      | Did not transform | 1.35 | 1.35    |
| 160 | Screening_67  | Screening | >0.770 | 0.837 | 1 | 12.4 | 11.9 | 2.5          | Strongyloides | No Rx                                                 | m | 46.0 | Positive | Black                      | Lost to followup  | 1.25 | 1.75    |
| 137 | Screening_68  | Screening | <0.770 | 0.716 | 0 | n/a  | 27.0 | 2.0          | Strongyloides | No Rx                                                 | f | 56.0 | Positive | Other                      | Did not transform | 1.80 | 1.80    |
| 35  | Screening_69  | Screening | <0.770 | 0.706 | 0 | n/a  | 6.0  | Missing data | HAM           | No Rx                                                 | f | 53.0 | Positive | Black                      | Lost to followup  | 2.55 | 3.05    |
| 155 | Screening_70  | Screening | <0.770 | 0.660 | 0 | n/a  | 2.8  | Missing data | HAM           | No Rx                                                 | f | 86.0 | Negative | Black                      | Lost to followup  | 0.50 | 1.00    |
| 211 | Screening_71  | Screening | <0.770 | 0.701 | 0 | n/a  | 17.7 | Missing data | HAM           | No Rx                                                 | m | 73.0 | Unknown  | Indian/Pakistan/Bangladesh | Lost to followup  | 0.00 | 0.50    |
| 30  | Screening_72  | Screening | <0.770 | 0.765 | 1 | 5.8  | 22.7 | 1.6          | HAM           | No Rx                                                 | f | 73.0 | Negative | Black                      | Lost to followup  | 4.01 | 4.51    |
| 189 | Screening_73  | Screening | <0.770 | 0.698 | 0 | n/a  | 20.6 | 1.2          | HAM           | No Rx                                                 | f | 78.0 | Negative | Black                      | Lost to followup  | 0.28 | 0.78    |
| 45  | Screening_74  | Screening | <0.770 | 0.690 | 0 | n/a  | 2.9  | 2.9          | HAM           | Hydroxychloroquine                                    | m | 73.0 | Negative | White                      | Did not transform | 1.79 | 1.79    |
| 118 | Screening_75  | Screening | <0.770 | 0.687 | 0 | n/a  | 10.5 | 2.2          | HAM           | No Rx                                                 | f | 70.0 | Negative | Black                      | Did not transform | 1.03 | 1.03    |
| 123 | Screening_76  | Screening | <0.770 | 0.662 | 0 | n/a  | 8.9  | 1.4          | HAM           | Hydroxychloroquine                                    | f | 64.0 | Negative | Black                      | Did not transform | 1.27 | 1.27    |
| 190 | Screening_77  | Screening | <0.770 | 0.700 | 1 | 4.0  | 1.3  | 2.7          | HAM           | Cyclosporin                                           | m | 70.0 | Negative | Black                      | Lost to followup  | 0.00 | 0.50    |
| 174 | Screening_78  | Screening | <0.770 | 0.782 | 0 | n/a  | 21.8 | 3.4          | HAM           | Prednisolone/Hydroxychloroquine/Mycophenolate Mofetil | m | 51.0 | Negative | Black                      | Did not transform | 1.59 | 1.59    |
| 110 | Screening_79  | Screening | <0.770 | 0.667 | 0 | n/a  | 7.1  | 1.5          | HAM           | No Rx                                                 | f | 59.0 | Negative | Other                      | Did not transform | 1.61 | 1.61    |
| 212 | Screening_80  | Screening | <0.770 | 0.694 | 0 | n/a  | 22.0 | 3.2          | HAM           | No Rx                                                 | f | 51.0 | Negative | White                      | Did not transform | 3.69 | 3.69    |
| 191 | Screening_81  | Screening | <0.770 | 0.695 | 0 | n/a  | 4.9  | 1.8          | HAM           | No Rx                                                 | f | 67.0 | Negative | Black                      | Did not transform | 1.90 | 1.90    |
| 126 | Screening_82  | Screening | <0.770 | 0.698 | 0 | n/a  | 16.1 | 2.0          | HAM           | No Rx                                                 | f | 46.0 | Positive | Indian/Pakistan/Bangladesh | Did not transform | 1.30 | 1.30    |
| 111 | Screening_83  | Screening | <0.770 | 0.633 | 0 | n/a  | 7.4  | 2.9          | HAM           | No Rx                                                 | f | 63.0 | Negative | Black                      | Did not transform | 1.84 | 1.84    |
| 127 | Screening_84  | Screening | <0.770 | 0.590 | 0 | n/a  | 13.0 | 3.4          | HAM           | No Rx                                                 | f | 57.0 | Negative | Other                      | Did not transform | 1.88 | 1.88    |
| 156 | Screening_85  | Screening | <0.770 | 0.645 | 0 | n/a  | 5.7  | Missing data | HAM           | Methotrexate                                          | f | 48.0 | Positive | Black                      | Lost to followup  | 4.85 | 5.35    |
| 112 | Screening_86  | Screening | <0.770 | 0.679 | 0 | n/a  | 17.1 | 1.6          | HAM           | No Rx                                                 | f | 64.0 | Unknown  | Black                      | Did not transform | 1.25 | 1.25    |
| 128 | Screening_87  | Screening | <0.770 | 0.633 | 0 | n/a  | 10.3 | 2.3          | HAM           | Methotrexate                                          | f | 61.0 | Negative | Black                      | Did not transform | 0.92 | 0.92    |
| 129 | Screening_88  | Screening | <0.770 | 0.669 | 0 | n/a  | 9.1  | 2.5          | HAM           | Methotrexate/Prednisolone                             | m | 61.0 | Negative | Black                      | Did not transform | 1.86 | 1.86    |
| 143 | Screening_89  | Screening | <0.770 | 0.710 | 0 | n/a  | 19.1 | 1.6          | HAM           | Methotrexate                                          | m | 66.0 | Negative | Black                      | Did not transform | 0.08 | 0.08    |
| 142 | Screening_90  | Screening | <0.770 | 0.617 | 0 | n/a  | 8.9  | 2.6          | HAM           | No Rx                                                 | m | 53.0 | Unknown  | Black                      | Did not transform | 1.02 | 1.02    |
| 200 | Screening_91  | Screening | <0.770 | 0.699 | 0 | n/a  | 24.2 | 1.3          | HAM           | Methotrexate                                          | f | 52.0 | Negative | Black possible             | Did not transform | 1.26 | 1.26    |
| 143 | Screening_92  | Screening | <0.770 | 0.729 | 0 | n/a  | 6.6  | 1.9          | HAM           | No Rx                                                 | f | 73.0 | Negative | Black                      | Did not transform | 1.25 | 1.25    |
| 76  | Screening_93  | Screening | <0.770 | 0.745 | 0 | n/a  | 7.7  | 1.9          | HAM           | No Rx                                                 | f | 59.0 | Negative | Black                      | Did not transform | 2.45 | 2.45    |
| 97  | Screening_94  | Screening | <0.770 | 0.623 | 0 | n/a  | 10.8 | 1.8          | HAM           | Methotrexate                                          | f | 76.0 | Negative | Black                      | Did not transform | 1.58 | 1.58    |
| 197 | Screening_95  | Screening | <0.770 | 0.749 | 1 | 8.7  | 9.7  | Missing data | HAM           | No Rx                                                 | f | 63.0 | Positive | Black                      | Lost to followup  | 0.00 | 0.50    |
| 157 | Screening_96  | Screening | <0.770 | 0.722 | 0 | n/a  | 20.5 | 3.1          | HAM           | No Rx                                                 | m | 54.0 | Negative | Black                      | Did not transform | 4.00 | 4.00    |
| 144 | Screening_97  | Screening | <0.770 | 0.682 | 0 | n/a  | 8.5  | 1.7          | HAM           | Methotrexate                                          | m | 53.0 | Unknown  | Black                      | Did not transform | 1.70 | 1.70    |
| 113 | Screening_98  | Screening | >0.770 | 0.788 | 2 | 19.7 | 31.5 | 3.2          | HAM           | No Rx                                                 | f | 55.0 | Negative | Black                      | Did not transform | 1.65 | 1.65    |
| 192 | Screening_99  | Screening | <0.770 | 0.647 | 0 | n/a  | 15.3 | 1.8          | HAM           | No Rx                                                 | m | 81.0 | Negative | Black                      | Lost to followup  | 0.00 | 0.50    |
| 130 | Screening_100 | Screening | <0.770 | 0.715 | 0 | n/a  | 14.2 | 1.3          | HAM           | Methotrexate                                          | m | 63.0 | Unknown  | Black                      | Did not transform | 1.21 | 1.21    |
| 145 | Screening_101 | Screening | <0.770 | 0.688 | 0 | n/a  | 8.6  | 3.0          | HAM           | No Rx                                                 | f | 52.0 | Negative | Black                      | Did not transform | 1.39 | 1.39    |
| 268 | Screening_102 | Screening | <0.770 | 0.695 | 0 | n/a  | 1.2  | 0.8          | HAM           | Methotrexate/Prednisolone                             | m | 79.0 | Negative | White                      | Did not transform | 1.36 | 1.36    |
| 114 | Screening_103 | Screening | <0.770 | 0.746 | 0 | n/a  | 37.4 | 2.5          | HAM           | No Rx                                                 | f | 68.0 | Negative | Black                      | Did not transform | 2.26 | 2.26    |
| 276 | Screening_104 | Screening | <0.770 | 0.662 | 0 | n/a  | 1.9  | Missing data | HAM           | No Rx                                                 | m | 61.0 | Unknown  | Black                      | Did not transform | 0.52 | 0.52    |
| 146 | Screening_105 | Screening | <0.770 | 0.709 | 0 | n/a  | 12.4 | 2.3          | HAM           | No Rx                                                 | f | 64.0 | Unknown  | Middle Eastern             | Did not transform | 1.28 | 1.28    |
| 193 | Screening_106 | Screening | <0.770 | 0.695 | 0 | n/a  | 0.6  | Missing data | Uveitis       | No Rx                                                 | f | 89.0 | Unknown  | Black                      | Lost to followup  | 0.00 | 0.50    |

\* abbreviations

\*\*\* Lymphocyte count 5 months pre DCI-flow assay; 6 months pre treatment

\*\*\*\* Lymphocyte count from 2 months pre DCI-flow assay

\*\*\*\*\* transient lymphocytosis

\*\*\*\*\* Occasional lymphocyte count >4x10<sup>9</sup>/L, not persistent